Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer
Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures such as sentinel lymph node mapping may improve the ability
 to detect cancer that has spread to the lymph nodes.

 PURPOSE: This clinical trial is studying how well sentinel lymph node mapping works in
 detecting cancer that has spread to the lymph nodes in patients who are undergoing surgery
 for stage I non-small cell lung cancer.
OBJECTIVES:

 Primary

 -  Determine the feasibility and accuracy of intraoperative sentinel lymph node mapping
 using technetium Tc 99 sulfur colloid in patients with stage I non-small cell lung
 cancer.

 -  Determine the percentage of patients in which at least 1 positive sentinel lymph node is
 identified using this procedure.

 -  Determine the percentage of patients undergoing this procedure who are found to have
 positive sentinel lymph nodes with no metastases in other intrathoracic lymph nodes.

 Secondary

 -  Determine the percentage of patients undergoing this procedure whose disease stage is
 upgraded due to detection of micrometastases in sentinel lymph nodes.

 -  Correlate the presence of micrometastases in sentinel lymph nodes with survival in
 patients undergoing this procedure.

 -  Determine the percentage of patients undergoing this procedure with "skip metastases"
 pattern (NZ) sentinel lymph nodes.

 OUTLINE: This is a multicenter study.

 Patients receive an intraoperative intratumoral injection of technetium Tc 99 sulfur colloid.
 At least 10 minutes later, patients undergo sentinel lymph node mapping using a gamma probe.
 Patients then undergo sentinel lymph node dissection and tumor resection. Pathology assays
 are performed using sentinel lymph node tissue, including hematoxylin and eosin staining,
 serial sections, and immunohistochemistry using the AE1/AE3/PCK2b cytokeratin antibody.

 Patients are followed every 6 months for 2 years and then annually thereafter.
1. Patients with clinical stage I lung cancer for whom surgical resection is planned are
 eligible. Histologic confirmation of lung cancer is not required prior to registration
 or surgical exploration. Preoperative mediatinoscopy is allowed but not required in
 those patients with indications for mediatinoscopy. It is preferred that that
 mediatinoscopy be done at a different setting (prior to registration), but the
 procedure may be done at the same setting as the lobectomy.

 2. No prior therapy for this diagnosis.

 3. No prior treatment with mediastinal radiation therapy.

 4. Age ≥ 18 years of age.

 5. ECOG performance status: 0-2.